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Identification of a Conserved Motif
Required for mTOR Signaling
changes characteristic of nutrient deprivation [3]. A role
for mTOR in a nutritional checkpoint is most likely con-
served in mammals, as downstream targets of mTOR,
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2 Freie Universitaet Berlin karyotic initiation factor 4E (eIF4E) binding protein1 (4E-
Institut fuer Biochemie BP1) are sensitive to amino acid levels [4].
Thieleallee 63, 14195 In mammalian cells, it is believed that mTOR partici-
Germany pates in the regulation of cell growth and proliferation
through regulation of translation via the S6Ks 1 and
2 and the 4E-BPs 1, 2, and 3 [5]. In quiescent cells,
hypophosphorylated 4E-BP1 binds to eIF4E and inhibits
Summary eIF4E-dependent translation of CAP containing mRNAs
with highly structured 5 untranslated regions (UTR) [5].
Background: The mammalian target of rapamycin This subset of mRNAs tends to encode proteins impor-
(mTOR) controls the translation machinery via activation tant for cell proliferation, such as c-Myc and cyclin D1
of S6 kinases 1 and 2 (S6K1/2) and inhibition of the [6]. S6K1 and S6K2 phosphorylate the 40S ribosomal
eukaryotic initiation factor 4E (eIF4E) binding proteins protein S6, which may enable the efficient translation
1, 2, and 3 (4E-BP1/2/3). S6K1 and 4E-BP1 are regulated of a subset of mRNAs containing a terminal oligopolypy-
by nutrient-sensing and mitogen-activated pathways. rimidine (TOP) track at the 5 end. Many of these mRNAs
The molecular basis of mTOR regulation of S6K1 and encode proteins of the translational machinery, such as
4E-BP1 remains controversial. ribosomal proteins and elongation factors [7].
The work from mammalian and Drosophila systems
Results: We have identified a conserved TOR signaling suggests that S6K1 and 4E-BP1 are capable of integrat-
(TOS) motif in the N terminus of all known S6 kinases ing signaling from mitogen- and nutrient-regulated path-
and in the C terminus of the 4E-BPs that is crucial for ways [5]. Nutrient-dependent signaling is mediated by
phosphorylation and regulation S6K1 and 4E-BP1 activi- mTOR, while mitogen-dependent signaling is mediated
ties. Deletion or mutations within the TOS motif signifi- through (PI3K)-dependent and -independent inputs. The
cantly inhibit S6K1 activation and the phosphorylation mTOR inhibitor rapamycin blocks S6 kinase activation
of its hydrophobic motif, Thr389. In addition, this se- and full 4E-BP1 phosphorylation by all agonists, demon-
quence is required to suppress an inhibitory activity strating the requirement for an intact mTOR signaling
mediated by the S6K1 C terminus. The TOS motif is pathway [5, 8, 9].
essential for S6K1 activation by mTOR, as mutations The mechanisms by which mTOR regulates S6K1 and
in this motif mimic the effect of rapamycin on S6K1 4E-BP1 phosphorylations are controversial. It is not
phosphorylation, and render S6K1 insensitive to clear whether mTOR directly phosphorylates S6K1and
changes in amino acids. Furthermore, only overexpres- 4E-BP1, activates intermediate kinases, or inhibits a
sion of S6K1 with an intact TOS motif prevents 4E-BP1 phosphatase [10]. Studies using rapamycin have shown
phosphorylation by a common mTOR-regulated modu- that mTOR regulates the phosphorylation of several
lator of S6K1 and 4E-BP1.
sites in S6K1, namely, Thr389, Thr229, and Ser404 [11,
12]. Thr389 appears to be the main target of mTOR
Conclusions: S6K1 and 4E-BP1 contain a conserved
regulation in S6K1, because it is rapidly and completely
five amino acid sequence (TOS motif) that is crucial for
dephosphorylated after rapamycin treatment [13].their regulation by the mTOR pathway. mTOR seems to
Here we have focused on how mTOR signals to itsregulate S6K1 by two distinct mechanisms. The TOS
downstream target, S6K1. We have identified a highlymotif appears to function as a docking site for either
conserved sequence in S6K1 that is essential for mTOR-mTOR itself or a common upstream activator of S6K1
dependent signaling. We refer to the sequence as theand 4E-BP1.
TOR signaling (TOS) motif. Through the use of a variety
of S6K1 deletion and phosphorylation site mutants, we
show that mTOR regulation of S6K1 involves two distinctIntroduction
regions of the protein. One input through the N-terminal
TOS motif leads to the phosphorylation of Thr389, andmTOR, the mammalian target of rapamycin (also re-
the other one requires the TOS motif to release a nega-ferred to as FRAP, RAFT, and RAPT) [1] is a member of
tive regulatory activity mediated by the C terminus ofa superfamily of protein serine/threonine kinases termed
S6K1. The importance of the TOS motif in mTOR signal-PIK-related kinases [2]. TOR from budding yeast and
ing is underscored by its identification in other mTOR-Drosophila functions to monitor nutrient availability, as
regulated proteins. The TOS motif is also conservedTOR deletions in these organisms result in physiological
throughout evolution in 4E-BPs. Mutation of the domain
in 4E-BP1 similarly blocks its mitogen-dependent phos-
phorylation.3 Correspondence: jblenis@hms.harvard.edu
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Results
Identification of a Conserved Region in the N
Terminus of S6K1 that Is Essential
for Its Activation
Deletion of the N-terminal 30 amino acids in the S6K1
II isoform (or 53 amino acids in the I isoform) inhibits
S6K1 activity and phosphorylation as does the mTOR
inhibitor rapamycin [11, 14, 15]. Thus, the N terminus of
S6K1 has been suggested to participate in its regulation
by the mTOR pathway. S6 kinases from all species
tested to date are rapamycin sensitive and therefore
regulated by TOR, indicating the possibility that a con-
served N-terminal domain might mediate the regulation
of S6 kinases by TOR [16–20]. While the amino acid
sequence of the N terminus is highly divergent between
S6K1 and S6K2 and across species, there exists a five
amino acid sequence in S6K1, FDIDL (amino acids 5–9),
that is evolutionary conserved (Figure 1A). To determine
the importance of this sequence for S6K1 function, we
deleted it in S6K1 (S6K1-NT2) and tested kinase activ-
ity in starved, insulin-stimulated, or rapamycin-treated
cells. Similar to the effect of deleting the first 30 amino
acids in S6K1 (S6K1-NT) [14, 15], deletion of the con-
served N-terminal sequence almost completely abro-
gated the activity of S6K1 (Figure 1B). Similar results
were seen for the deletion of the conserved sequence
in S6K2 (data not shown).
Next we introduced point mutations in S6K1 within
this conserved sequence to determine which amino
acids are critical for the regulation of S6K1 activity. We
mutated the bulky phenylalanine residue number 5
(numbering for rat S6K1 II isoform) to alanine (F5A),
the two charged aspartic acid residues numbers 6 and
8 to alanines (D6/8A), or the hydrophobic leucine and
isoleucine residue numbers 7 and 9 to alanine (L7/9A).
Each of the introduced point mutations had a dramatic
inhibitory effect on S6K1 activity (Figure 1C). These re-
sults demonstrate that this highly conserved N-terminal
domain is essential for S6K1 activation and that several
of its residues are required for S6K1 activity. We refer
to this sequence as the TOS motif and provide evidence
that it is indeed required for mTOR signaling. Since the
F5A mutation generated a mutant allele essentially de-
void of any activity and therefore mimics the loss of the Figure 1. Identification of a Conserved Domain in the N Terminus
of S6 Kinases Essential for Kinase ActivityTOS motif, we used this construct for further character-
(A) Sequence alignment of the first 30 amino acids of S6K1 (human),ization.
S6K (Xenopus laevis), S6K (Drosophila melanogaster), S6K (C. ele-
gans), S6K2 (human), S6K (Artemnia fransiscana), and S6K (Aplysia).
Identical (black box) and conserved (shadowed box) amino acidsThe F5A Mutation Inhibits Phosphorylation
are highlighted. HEK293 cells were transfected with (B) HA-S6K1of S6K1 at Thr389 and Thr229
wild-type (wt) or HA-S6K1-NT2 (NT2) and (C) HA-S6K1 wild-type
Since S6K1 activation correlates with multisite phos- (wt), HA-S6K1-F5A (F5A), HA-S6K1-L7/9A (L7/9A), or HA-S6K1-D6/
phorylation, we next determined which phosphorylation 8A (D6/8A). Transfected cells were starved, stimulated, and lysed
as described in Experimental Procedures. Protein expression levelsevents of S6K1 required an intact TOS motif. To do this,
were assayed by immunoblotting with -HA-antibody (secondwe employed phosphospecific antibodies raised against
panel), and kinase assays were performed as described in Experi-various S6K1 phosphorylation sites (Figure 2). The F5A
mental Procedures. Quantification of kinase assay (upper panel) andmutation completely inhibited insulin-stimulated Thr389
autoradiogram of in vitro S6 phosphorylation (lower panel).
phosphorylation (Figure 2). The effect was similar to
the inhibition of Thr389 phosphorylation observed with
rapamycin [13]. The F5A mutation significantly but not caused by the inhibition of Thr389 phosphorylation and/
or activation of a phosphatase. The F5A mutation did notcompletely inhibited Thr229 phosphorylation (Figure 2).
The inhibition of Thr229 phosphorylation could be a pri- significantly affect the phosphorylation of the proline-
directed Ser371 site, also located in the linker regionmary effect of the F5A mutation or a secondary effect
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only about 5%–15% of the insulin-stimulated S6K1 wild-
type kinase activity, whereas S6K1-CT has about 50%–
75% of the wild-type activity. Importantly, S6K1-CT,
unlike the wild-type protein, is partially rapamycin resis-
tant (Figure 3B and [14, 15]). The activity of S6K1-CT in
the presence of rapamycin is comparable to the insulin-
stimulated, rapamycin-resistant activity of S6K1-NT/
CT and F5A-CT, suggesting that the deletion of the
C terminus is contributing to the observed rapamycin
resistance of S6K1-CT and S6K1-NT/CT (Figure 3B).
These data suggest that deletion of the C terminus might
release a rapamycin-sensitive inhibitory function, re-
sulting in a mitogen-dependent but mTOR-independent
activation of S6K1. The N terminus appears to mediate
a positive mTOR-regulated input that is absent in S6K1-
NT and S6K1-NT/CT but still inhibited by rapamycin
in S6K1-CT. Similar results were seen for N- and/or
C-terminal truncation mutants of S6K2 (data not shown).
Thus, the single F5A point mutation mimicked the effect
of deleting the entire N-terminal domain (Figure 4 and
[14, 15]).
Since the F5A mutation had the most severe effect
on Thr389 phosphorylation (Figure 2), we wanted to de-
termine if mutation of this site to an acidic residue to
mimic phosphorylation was sufficient to overcome the
Figure 2. The F5A Mutation Inhibits Thr389 and Thr229 Phosphory-
inhibitory effect of the F5A mutation on S6K1 kinaselation
activity. Replacing Thr389 with glutamic acid (E389) par-HEK293 cells were transfected with HA-S6K1 wild-type (wt) or HA-
tially restored the activity of the F5A mutant (F5A-E389),S6K1-F5A (F5A). Transfected cells were starved, rapamycin treated,
and this was largely rapamycin resistant (Figure S2 instimulated, and lysed as described in Experimental Procedures.
Protein expression levels were assayed by immunoblotting with the Supplementary Material available with this article
-HA-antibody (upper panel). For evaluation of the in vivo phosphor- online).
ylation of Thr389, Thr229, Thr371, Ser411, and Thr421/Ser424, HA- We next combined the C-terminal deletion with the
S6K1 and HA-S6K1-F5A were immunoprecipitated with an anti-HA-
E389 point mutation in wild-type and F5A S6K1s, creat-antibody, and phosphorylation was evaluated by immunoblotting
ing E389-CT and F5A-E389-CT, respectively. Delet-with -S6K1-P-Thr389 phosphopeptide-specific antibody, -S6K1-
ing the C terminus and introducing the Thr389Glu muta-P-Thr229 phosphopeptide-specific antibody, -S6K1-P-Thr371
phosphopeptide-specific antibody, -S6K1-P-Ser-411 phospho- tion into F5A completely restored its activity to the level
peptide-specific, and -S6K1-P-Thr421/Ser424 phosphopeptide- of the stimulated wild-type enzyme and conferred com-
specific antibody. plete rapamycin resistance, making it indistinguishable
from E389-CT (Figure 3C). The data suggest that sig-
naling through the TOS motif is required for Thr389 phos-
(Figure 2). Phosphorylation of the proline-directed phorylation and for the inhibition of a negative regulatory
C-terminal phosphorylation sites Ser411, Thr421/Ser424 effect mediated by the C terminus. In contrast to F5A-
were also not significantly affected by the F5A mutation E389CT, F5A-E389D3E, only partially rescued the effectunder these conditions (Figure 2). The phosphorylation of the F5A mutation, and this mutant was still partially
pattern of these sites in F5A is comparable to their phos- rapamycin sensitive (Figure S2). Thus, overcoming the
phorylation in S6K1-NT [11] and in rapamycin-treated inhibitory effect of the C terminus appears to require
wild-type S6K1 [13, 21], which is once again consistent more than phosphorylation of known C-terminal sites.
with the TOS motif being critical for mTOR signaling to
S6K1.
The S6K1 F5A Mutation Prevents Amino Acid
Signaling via mTOR toward S6K1The F5A Point Mutation Mimics Deletion
of the N Terminus To further investigate the role of the TOS motif in specifi-
cally mediating mTOR signaling to S6K1, we wanted toWe wanted to determine if the F5A point mutation mim-
icked the effect of deleting the N terminus of S6K1. It determine if the F5A mutation makes S6K1 insensitive
to changes in amino acid levels. Amino acid withdrawalhas been reported that the additional deletion of the
C terminus rescues the inhibitory effect of the N-terminal selectively inhibits mTOR signaling similar to rapamycin.
Mitogen-regulated signaling pathways that are involveddeletion and renders S6K1 (S6K1NT/CT) completely
rapamycin resistant [14, 15]. Deletion of the C terminus in S6K1 regulation, like the PI3K and MAPK pathways,
are not sensitive to changes in amino acids [22–24].in the F5A background (F5A-CT) only partially restored
S6K1 activity, which, like S6K1-NT/CT, was completely Here we used F5A-CT instead of F5A, because the
F5A allele has no activity. If S6K1CT is sensitive torapamycin resistant (Figure 3A). We compared the insu-
lin-stimulated activities of S6K1-NT/CT to S6K1 wild- changes in the level of amino acids but F5A-CT is not,
we could conclude that the TOS motif is necessary fortype and S6K1-CT. Like F5A-CT, S6K1-NT/CT has
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Figure 3. The F5A Point Mutation Mimics De-
letion of the 30 Amino Acids, and Its Activity
Is Partially Rescued by Deletion of the C Ter-
minus
HEK293 cells were transfected with (A) HA-
S6K1-F5A (F5A), S6K1-F5A-CT (F5A-CT),
or HA-S6K1 wild-type (wt); (B) HA-S6K1 wild-
type (wt), HA-S6K1CT (CT), or S6K1-NT/
CT (NT/CT); and (C) HA-S6K1 wild-type (wt),
HA-S6K1- E389CT (E389CT), HA-S6K1-
F5A (F5A), and HA-S6K1-F5A- E389CT
(F5A- E389CT). Transfected cells were
starved, stimulated, and lysed as described in
Experimental Procedures. Protein expression
levels were assayed by immunoblotting with
-HA-antibody (second panels), and kinase
assays were performed as described in Ex-
perimental Procedures. Quantification of ki-
nase assay (upper panels) and autoradiogram
of in vitro S6 phosphorylation (lower panels).
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Figure 4. The F5A Mutation Blocks Amino
Acid Signaling via mTOR toward S6K1
HEK293 cells were transfected with HA-
S6K1CT (CT) or HA-S6K1-F5A-CT (F5A-
CT). Transfected cells were stimulated and
lysed as described in Experimental Proce-
dures. Protein expression levels were as-
sayed by immunoblotting with-HA-antibody
(middle panels), and kinase assays were per-
formed as described in Experimental Proce-
dures. Quantification of kinase assay (upper
panels) and autoradiogram of in vitro S6
phosphorylation (lower panels).
amino acid signaling toward S6K1 and therefore respon- stream mTOR regulator. If this hypothesis is correct,
then overexpression of the F5A mutant should not inhibitsible for its regulation by mTOR. S6K1CT and F5A-
CT were modestly activated by insulin after 60 min 4E-BP1 phosphorylation. The 4E-BP1 mobility shift
upon insulin stimulation was inhibited by rapamycinof amino acid withdrawal. A more robust activation of
S6K1CT was seen with a combination of amino acids (Figure 5). Like rapamycin treatment, overexpression of
S6K1 wild-type, kinase dead (K100R), or E389D3E con-and insulin (Figure 4), consistent with the model that
S6K1 requires a nutrient-sensing and a growth factor- structs inhibited insulin-induced 4E-BP1 phosphoryla-
tion. In contrast, overexpression of F5A or F5A-E389D3Emediated input for its full activation. F5A-CT (Figure
4), like NT/CT (data not shown and [24]), did not show mutants did not inhibit 4E-BP1 phosphorylation, indicat-
ing that an intact TOS motif is required to block signalinga significant difference between activation of these al-
leles by insulin only or a combination of insulin and by a common 4E-BP1 and S6K1 regulator (Figure 5).
Inhibition of 4E-BP1 phosphorylation was independentamino acids. These data show mutations in the TOS
motif make S6K1 insensitive to changes in amino acids, of S6K1 activity and strictly correlated with the presence
of an intact TOS motif.demonstrating that this sequence is essential for mTOR
signaling toward S6K1.
Identification of a TOS Motif in 4E-BP1
If the TOS motif plays a general role in mTOR signaling,4E-BP1 Phosphorylation Is Inhibited
by Overexpression of S6K1 with we predicted that it would be present in other mTOR
targets. 4E-BP1 is a well-characterized target of mTORan Intact TOS Motif
We wanted to further establish the role for the TOS motif signaling. Like S6K1, 4E-BP1 is in vitro phosphorylated
by mTOR and several of its phosphorylation sites arein mTOR signaling to S6K1. Previous studies suggest
that 4E-BP1 and S6K1 share a limiting, rapamycin-sensi- sensitive to rapamycin [5]. We identified a potential TOS
motif in the C terminus of 4E-BP1 (FEMDI) that is con-tive regulator that functions as a bifurcation point imme-
diately upstream of S6K1 [25]. Insulin-stimulated phos- served between all three human 4E-BPs and Drosophila
4E-BP (Figure S3). Mutation of the phenylalanine 114 tophorylation of 4E-BP1, as assessed by retarded band
migration on SDS-PAGE immunoblots, is inhibited by alanine in this motif inhibited insulin-dependent phos-
phorylation of 4E-BP1 (Figure 6), suggesting that thisoverexpression of S6K1. Thus, overexpression of S6K1
appears to sequester a common S6K1 and 4E-BP1 regu- sequence is crucial for 4E-BP1 phosphorylation and
therefore also required for mTOR signaling towardlator. Inhibition of the 4E-BP1 and S6K1 phosphorylation
by ectopic S6K1 overexpression seems to be specific 4E-BP1.
for the mTOR pathway, because a similar inhibition of
4E-BP1 and S6K1 phosphorylation is seen with rapa- Discussion
mycin [25].
We hypothesized that the TOS motif might mediate Rapamycin inhibits S6K1 activation and 4E-BP1 phos-
phorylation by all known stimuli, indicating that mTORsignaling by this common regulator and that the F5A
mutation would prevent S6K1 from sequestering an up- signaling is essential for these phosphorylation-regu-
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Figure 5. Expression of S6K1 with an Intact
TOS Domain Is Required to Inhibit 4E-BP1
Phosphorylation
HEK293 cells were cotransfected with HA-
4E-BP1 and the empty vector pRK7 (A), HA-
S6K1 wild-type (wt) (B), HA-S6K1- F5A (F5A)
(C), HA-S6K1-K100R (K100R) (D), HA-S6K1-
E389D3E (E389D3E) (E), or HA-S6K1-F5A-
E389D3E (F5A-E389D3E) (F). Transfected cells
were starved and lysed as described in Ex-
perimental Procedures. Detection of HA-4E-
BP1 by immunoblotting with -HA-antibody
(upper panel) and protein expression levels
of S6K1 constructs were assayed by immu-
noblotting with -HA-antibody (bottom
panel). Autoradiogram of S6 in vitro phos-
phorylation (second panel).
lated processes. The molecular mechanisms whereby mTOR regulation of the C-terminal inhibitory pseudo-
substrate domain is through phosphorylation. MutationmTOR regulates its downstream targets are controver-
sial. It is not clear if mTOR regulates S6 kinases and 4E- of the rapamycin-sensitive site Ser404 to Asp or all of
the other known phosphorylation sites in the C terminusBPs via direct phosphorylation, by activating an interme-
to acidic residues (S6K1-D3E) did not change rapamycindiary kinase, and/or by inhibiting a phosphatase [5, 10].
sensitivity of S6K1 activity (data not shown and [13,We have identified a novel conserved motif (TOS mo-
15]), suggesting that the mTOR input mediated by thetif) in the N terminus of S6K1 and in the C terminus of
C terminus of S6K1 is not regulated by phosphorylation4E-BP1 that is crucial for their phosphorylation by the
of known sites but more likely by another mechanismmTOR pathway. Our results indicate that mTOR regu-
possibly involving a phosphatase.lates phosphorylation of S6K1 by at least two mecha-
Data from budding yeast provides a compelling argu-nisms, both requiring the presence of the newly identi-
ment that TOR may function to regulate a phosphatasefied TOS motif. The first mechanism appears to provide
[26, 27], and evidence already exists for regulation ofa positive input regulating phosphorylation of the critical
S6K1 phosphorylation by a rapamycin-activated phos-hydrophobic motif site Thr389 directly or through a
phatase [28, 29]. The rapamycin-sensitive dephosphory-mTOR-regulated kinase. Although mutations in the TOS
lation of different sites in S6K1, such as Thr229, Thr389,domain (F5A) cause complete loss of kinase activity and
and Ser404 (Figure 2 and [13, 14]), may be consistentinhibition of Thr389 phosphorylation (Figures 1C and 2),
with the activation of a PP2A-like phosphatase. There-mutation of the Thr389 site to an acidic residue to mimic
fore, in addition to providing a direct input, mTOR mightphosphorylation in F5A only partially rescued S6K1 ac-
regulate its targets by inhibiting a phosphatase thattivity (Figure S2). An additional deletion of the C-terminal
binds to the C terminus and is able to dephosphorylatedomain (F5A-E389CT) completely overcame the inhibi-
several phosphorylation sites in S6K1. This would allowtory effect of the F5A mutation, making this S6K1 mutant
for a very dynamic regulation of S6K1 activity in re-fully active and rapamycin resistant (Figure 3C), sug-
sponse to nutrients and mitogenic agonists.gesting a second C-terminal-mediated regulatory mech-
A previous model, based on the observation thatanism that requires the TOS motif to be suppressed.
S6K1-CT is mitogen regulated and still rapamycin sen-Thus, mTOR might suppress the autoinhibitory function
sitive, whereas S6K1-NT/CT is not rapamycin sensi-of the C terminus or inhibit the activity of a C-terminally-
tive, suggested that a PP2A-like phosphatase that isassociated phosphatase. One possible mechanism for
inhibited by mTOR would bind to the N terminus and
dephosphorylate S6K1 [11, 14]. This model does not
take into account, however, the fact that S6K1-CT is
partially rapamycin resistant and that its activity in the
presence of rapamycin is comparable to the mitogen-
stimulated activity of S6K1-NT/CT (Figure 3B). These
previous experiments also did not address the possibil-
ity of phosphatase interaction with the C terminus. Our
data suggest rather that the deletion of the C terminus
contributes to the observed rapamycin resistance (Fig-
ure 3B).
Our data indicate that the TOS motif functions to medi-
ate an interaction between S6K1 and an upstream mTOR
regulator important for regulation of 4E-BP1 and S6K1.
Overexpression of S6K1 with an intact TOS motif inhib-Figure 6. Identification of Conserved Motif in C Terminus of 4E-BPs
ited 4E-BP1 and S6K1 phosphorylation at sites known
Point mutation F114A in potential TOS motif in 4E-BP1 causes loss
to be regulated by mTOR, suggesting the existence ofof phosphorylation. HEK293 cells were transfected with HA-4E-BP1
a limiting activator functioning in the mTOR pathwayor HA-4E-BP1 F114A. 4E-BP1 was detected by immunoblotting with
-HA-antibody. immediately upstream of S6K1 (Figure 5). Since the inhi-
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the amino acid withdrawal, cells were first incubated in serum-freebition of kinase activity caused by deletion or mutations
DMEM for 20 hr, washed once with Dulbecco’s phosphate-bufferedof the TOS motif can be rescued (Figure 3C), it is unlikely
saline (D-PBS, containing 0.1 g/liter CaCl2), and incubated in thethat these mutations are causing structural changes in
same buffer for 60 min. Readdition of amino acids involved changing
S6K1 that render the enzyme kinase inactive. mTOR is the medium to D-PBS containing a “5 amino acid mixture” (MEM
thought to function as a nutritional checkpoint, as its Amino Acids Solution, GibcoBRL).
downstream targets, such as S6K1, are sensitive to
changes in amino acid levels [22–24]. Mutations in the Immunoblotting
Immunoblotting with anti HA- or phosphospecific antibodies as de-TOS motif renders S6K1 insensitive to changes in amino
scribed previously [30].acid levels (Figure 4), providing additional evidence that
mTOR signaling is mediated by the TOS motif in S6K1.
Immune-Complex Kinase Assay
Immune-complex kinase assay was carried out as described pre-
Conclusions viously [30].
S6K1 contains in its N terminus a conserved sequence
(TOS motif) that is crucial for its regulation by the mTOR Supplementary Material
pathway. mTOR seems to regulate S6K1 by two distinct Supplementary Material including figures showing a schematic rep-
resentation of S6K1, the effect of mutations of phosphorylation sitesmechanisms. One may involve direct phosphorylation
in S6K1 wild-type (E389 and E389D3E) and F5A (F5A-E389 and F5A-of Thr389 by mTOR or indirect regulation by a mTOR-
E389D3E) on kinase activity, and a sequence alignment of humanregulated kinase, the other mechanism is required to
4E-BP1, 2, and 3 and Drosophila 4E-BP is available at http://images.suppress an inhibitory activity mediated by the S6K1 cellpress.com/supmat/supmatin.htm.
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